Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety rollover study of luspatercept
2018-002915-93Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Feb 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of luspatercept in Thalassaemia and Hematologic And Lymphatic Diseases, sponsored by Celgene Corporation. Primary endpoint: Adverse events (AEs). Started Feb 2019; status: active.
02
Drugs
luspatercept
03
Conditions
ThalassaemiaHematologic And Lymphatic Diseases
Beyond the preview
Go deeper on 2018-002915-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002915-93.